Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) has shared an update.
Sawai Group Holdings reported a 6.7% rise in revenue to ¥201.7 billion for the year ended March 31, 2026, with operating profit surging more than threefold as its core domestic pharmaceuticals business improved after exiting its U.S. operations. Profit attributable to owners of the parent declined 12.8% to ¥10.4 billion due to the absence of prior-year discontinued-operation effects, but profitability metrics strengthened, equity inched higher, and the company maintained a shareholder-friendly stance with a total annual dividend of ¥55 per share and guidance for further profit and earnings-per-share growth in fiscal 2027.
The group’s balance sheet remained solid, with total assets of ¥359.9 billion and an equity ratio just under 50%, though operating cash flow weakened while investing outflows increased, signaling active capital deployment. For the fiscal year ending March 31, 2027, Sawai forecasts modest revenue growth to ¥208.4 billion but a sharp recovery in earnings, projecting operating profit up 71.1% and profit attributable to owners of the parent up 78.2%, underlining management’s confidence in the profitability of its continuing Japanese generics business and providing clearer visibility for investors after a transitional period.
The most recent analyst rating on (JP:4887) stock is a Buy with a Yen2800.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. is a Japan-based pharmaceutical group listed on the Tokyo Stock Exchange. The company focuses on prescription medicines, notably generic drugs, and operates primarily in the domestic market after classifying its U.S. business as a discontinued operation, positioning itself as a key player in Japan’s healthcare and generics sector.
Average Trading Volume: 342,617
Technical Sentiment Signal: Buy
Current Market Cap: Yen207.1B
Learn more about 4887 stock on TipRanks’ Stock Analysis page.